Roche’s faricimab hits primary endpoint in wet AMD studies
Roche’s investigational bispecific antibody faricimab has hit the primary endpoint in two Phase III studies in people living with neovascular or wet age-related macular degeneration (nAMD).
In the identically designed studies – TENAYA and LUCERNE – faricimab, administered via injections at fixed intervals, met the primary endpoint, showing that people receiving the treatment achieved visual acuity outcomes that were non-inferior to those receiving Regeneron’s Eylea (aflibercept) injections every eight weeks.
Within both studies, nearly half (45%) of participants were treated with faricimab every 16 weeks during the first year.
“These results show the potential of faricimab as a new class of medicine that could extend time between treatments for people living with neovascular age-related macular degeneration,” said Levi Garraway, chief medical officer and head of Global Product Development, Roche.
Read more: http://www.pharmatimes.com/news/roches_faricimab_hits_primary_endpoint_in_two_wet_amd_studies_1361940
In the identically designed studies – TENAYA and LUCERNE – faricimab, administered via injections at fixed intervals, met the primary endpoint, showing that people receiving the treatment achieved visual acuity outcomes that were non-inferior to those receiving Regeneron’s Eylea (aflibercept) injections every eight weeks.
Within both studies, nearly half (45%) of participants were treated with faricimab every 16 weeks during the first year.
“These results show the potential of faricimab as a new class of medicine that could extend time between treatments for people living with neovascular age-related macular degeneration,” said Levi Garraway, chief medical officer and head of Global Product Development, Roche.
Read more: http://www.pharmatimes.com/news/roches_faricimab_hits_primary_endpoint_in_two_wet_amd_studies_1361940
